ABSTRACT
No disponible
Subject(s)
Humans , Female , Adolescent , Upper Extremity Deformities, Congenital/complications , Upper Extremity Deformities, Congenital , Cardiovascular Diseases/complications , Cardiovascular Diseases , Echocardiography , Fingers/abnormalities , Hand Deformities, Congenital/complications , Hand Deformities, Congenital/diagnosisSubject(s)
Abnormalities, Multiple/genetics , Abnormalities, Multiple/pathology , Heart Defects, Congenital/genetics , Heart Defects, Congenital/pathology , Heart Septal Defects, Atrial/genetics , Heart Septal Defects, Atrial/pathology , Heterozygote , Lower Extremity Deformities, Congenital/genetics , Lower Extremity Deformities, Congenital/pathology , T-Box Domain Proteins/genetics , Upper Extremity Deformities, Congenital/genetics , Upper Extremity Deformities, Congenital/pathology , Adolescent , DNA/genetics , Exons/genetics , Female , Humans , Pedigree , Penetrance , Phenotype , Polymerase Chain Reaction , Thumb/abnormalitiesABSTRACT
This article contains a review of major new developments in drug treatment and the impact they could have for the general cardiologist. New treatments for arrhythmias, chronic ischemic heart disease, and secondary prevention are changing the practice of clinical cardiology. In addition, recent publications on treatment adherence and therapeutic inertia are discussed. Finally, the work of the Clinical Cardiology and Outpatient Section of the Spanish Society of Cardiology during the last year is described.
Subject(s)
Cardiology/trends , Cardiovascular Agents/therapeutic use , Heart Diseases/drug therapy , Ambulatory Care , Anti-Arrhythmia Agents/therapeutic use , Atrial Fibrillation/drug therapy , Humans , Myocardial Ischemia/drug therapy , Secondary PreventionABSTRACT
Se revisan las principales novedades en tratamiento farmacológico y el impacto que pueden tener en la actividad clínica del cardiólogo generalista. Los nuevos tratamientos en el campo de las arritmias, la cardiopatía isquémica crónica y la prevención secundaria están cambiando la forma de actuar del cardiólogo clínico. Se revisa la literatura reciente sobre adherencia al tratamiento y sobre inercia terapéutica. Se describe la actividad que la Sección de Cardiología Clínica y Extrahospitalaria ha realizado en el último año (AU)
This article contains a review of major new developments in drug treatment and the impact they could have for the general cardiologist. New treatments for arrhythmias, chronic ischemic heart disease, and secondary prevention are changing the practice of clinical cardiology. In addition, recent publications on treatment adherence and therapeutic inertia are discussed. Finally, the work of the Clinical Cardiology and Outpatient Section of the Spanish Society of Cardiology during the last year is described (AU)
Subject(s)
Humans , Cardiovascular Agents/therapeutic use , Cardiovascular Diseases/drug therapy , Medication Adherence/statistics & numerical data , Atrial Fibrillation/drug therapy , Myocardial Ischemia/drug therapy , Arrhythmias, Cardiac/drug therapy , Secondary Prevention/methodsSubject(s)
Cardiology , Cardiology/trends , Heart Diseases/therapy , Humans , Physician's Role , SpainABSTRACT
No disponible
No disponible
Subject(s)
Humans , Cardiology/trends , Cardiovascular Diseases/epidemiology , Medicine/trends , Models, Cardiovascular , Risk Adjustment/methods , Myocardial Ischemia , Endocarditis, Bacterial , Heart Failure , Arrhythmias, CardiacABSTRACT
Ischemic heart disease has mistakenly been considered of little relevance to women because it occurs infrequently during the fertile years. This is despite the fact that a larger percentage of women than men die from cardiovascular disease. There are differences in cardiovascular risk factors and disease between females and males, including differences in clinical presentation, disease course, diagnostic criteria, prognosis, and treatment. There is a need for increased information and education, earlier and more aggressive control of risk factors, and a more appropriate approach to diagnosis and treatment. The American Heart Association has published guidelines on the prevention of cardiovascular disease in women and the European Society of Cardiology is planning to publish a scientific statement on the management of heart disease in women. Spanish cardiologists should also consider adopting a similar approach.
Subject(s)
Cardiovascular Diseases , Cardiovascular Diseases/diagnosis , Cardiovascular Diseases/epidemiology , Cardiovascular Diseases/therapy , Female , Humans , Prognosis , Risk Factors , Sex FactorsABSTRACT
De acuerdo con los objetivos de las monografías de Temas de Actualidad en Cardiología, y en lo que se refiere a avances en estimulación cardíaca durante el año 2005, conviene destacar para el clínico 3 aspectos de interés. El tratamiento coadyuvante en la insuficiencia cardíaca avanzada y refractaria mediante estimulación biventricular con marcapasos ha pasado a ser una indicación de tipo I, con lo que cabe esperar modificaciones en la práctica clínica. Por otra parte, la Sección de Estimulación Cardíaca, en nombre de la Sociedad Española de Cardiología, ha participado en la elaboración de un documento de consenso nacional sobre enfermedad del sueño donde quedan recogidas las diferentes alteraciones cardíacas relacionadas con el síndrome de apnea del sueño. Las enfermedades del ritmo cardíaco y, en especial, las bradiarritmias constituyen en la actualidad una línea novedosa de investigación para conocer la posibilidad de influir positivamente en la evolución de este síndrome mediante estimulación cardíaca permanente. Finalmente, se tratará sobre los sistemas diseñados para reducir la estimulación innecesaria en el ventrículo derecho que en muchas ocasiones se produce con las diversas modalidades de estimulación antibradicardia. Estos novedosos sistemas evitarán, en buena parte de los pacientes, los conocidos efectos perjudiciales que con frecuencia se observan durante la estimulación en el ápex de ventrículo derecho (AU)
Ischemic heart disease has mistakenly been considered of little relevance to women because it occurs infrequently during the fertile years. This is despite the fact that a larger percentage of women than men die from cardiovascular disease. There are differences in cardiovascular risk factors and disease between females and males, including differences in clinical presentation, disease course, diagnostic criteria, prognosis, and treatment. There is a need for increased information and education, earlier and more aggressive control of risk factors, and a more appropriate approach to diagnosis and treatment.The American Heart Association has published guidelines on the prevention of cardiovascular disease in women and the European Society of Cardiology is planning to (..) (AU)
